Hofseth BioCare announces global innovation partnership with Catalent to develop an OmeGo® sustained-release fish oil formulation
ALESUND, NORWAY – May 12, 2021 – Hofseth BioCare ASA (HBC), a Norwegian biotech company developing high quality ingredients and finished products, announced today that it has entered into a global innovation partnership with Catalent, the world’s leading provider of advanced delivery technology, development and manufacturing solutions for medicines , Biologics, cell and gene therapies, and consumer health products to develop a sustained-release formulation of HBC’s OmeGo® fish oil.
As part of the partnership, Catalent will use its proprietary OptiGel® DR technology to encapsulate OmeGo, HBC’s unique fish oil made from sustainable, traceable and fresh Norwegian Atlantic salmon. OptiGel DR technology enables an enteric release profile for capsules with no additional external coating, using a one-step manufacturing process that avoids the heat and drying of the coating process that could otherwise degrade the fish oil.
HBC is currently conducting studies to investigate the potential role of OmeGo fish oil in preventing disease progression and reducing inflammation, including in patients with inflammation caused by COVID-19. The results are expected in the coming months and offer deep insights into the potential of OmeGo fish oil to aid the body in resolving inflammation caused by a viral infection.
“Our research into the health benefits of our unique oil has come a long way in the past 18 months. We look forward to working with Catalent and hope to further expand the partnership and leverage the innovative oral technologies to ensure the delivery system is effective, ”commented Dr. Bomi Framroze, HBC Scientific Director. “OptiGel DR will enhance the OmeGo franchise, bring in advanced delivery technologies and raise its profile among the world’s leading healthcare companies.”
“This partnership is an exciting opportunity to combine the properties of a high quality ingredient with our new OptiGel DR capsule technology to create a product that offers consumers optimal benefits and experiences,” commented Dr. Aris Gennadios, President of Softgel and Oral Technologies, Catalan. “Our rich history and innovation in softgel technology has enabled us to develop a dosage form that delivers ingredients and formulations with an enteric release profile in robust capsules and with product performance that meets consumer expectations.”
Introduced by Catalent in 2020, OptiGel DR capsule technology gives innovators the ability to formulate products in a patient-preferred softgel dosage form with a sustained-release profile that offers many benefits, including protection from active ingredients caused by acid in the capsule can be broken down by the stomach and release these active ingredients directly in the intestine, where they are absorbed, possibly improving bioavailability. The technology also preserves the clarity of the capsule, which is important for HBC to reveal the distinctive color of OmeGo fish oil, and maintains the distinctive swallowability that consumers associate and prefer with softgel dosage forms.
You can find more information about OptiGel DR at https://consumerhealth.catalent.com/nutritional-supplements/dose-forms/optigel-dr-softgel-technology.